Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06428500 · ClinicalTrials.gov registry record · Phase 1
QTX3046 in Patients With KRAS G12D Mutations
A Phase 1 study of Advanced Solid Tumor, sponsored by Quanta Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 5
- Study locations
NCT06428500 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by Quanta Therapeutics. The registered enrollment target is 240 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT06428500, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by Quanta Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 5
- Study locations
Study Summary
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Cetuximab
- DRUG QTX3046
Study Locations (5)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics, LLC San Antonio - San Antonio
Michigan
- South Texas Accelerated Research Therapeutics, LLC Midwest - Grand Rapids
North Carolina
- Duke Cancer Center - Durham
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06428500
The ClinicalTrials.gov registry entry for NCT06428500 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% higher). The listed sponsor is Quanta Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT06428500 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06428500 about?
NCT06428500 is a clinical study titled "QTX3046 in Patients With KRAS G12D Mutations". Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
What is the current status of trial NCT06428500?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-05-30. Estimated completion is 2027-07-01.
What conditions does trial NCT06428500 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06428500?
The interventions under investigation include: Cetuximab (COMBINATION_PRODUCT), QTX3046 (DRUG).
Who is sponsoring clinical trial NCT06428500?
This trial is sponsored by Quanta Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06428500 being conducted?
This trial has 5 study locations across Michigan, North Carolina, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.